|
1.
|
Matsuno S, Egawa S, Fukuyama S, et al:
Pancreatic Cancer Registry in Japan: 20 years of experience.
Pancreas. 28:219–230. 2004.PubMed/NCBI
|
|
2.
|
Bramhall SR, Allum WH, Jones AG, Allwood
A, Cummins C and Neoptolemos JP: Treatment and survival in 13,560
patients with pancreatic cancer, and incidence of the disease, in
the West Midlands: an epidemiological study. Br J Surg. 82:111–115.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Parkin DM, Bray FI and Devesa SS: Cancer
burden in the year 2000. The global picture. Eur J Cancer. 37(Suppl
8): S4–S66. 2001.PubMed/NCBI
|
|
4.
|
Burris HA III, Moore MJ, Andersen J, et
al: Improvements in survival and clinical benefit with gemcitabine
as first-line therapy for patients with advanced pancreas cancer: a
randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
|
5.
|
Oettle H, Post S, Neuhaus P, et al:
Adjuvant chemotherapy with gemcitabine vs observation in patients
undergoing curative-intent resection of pancreatic cancer: a
randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar
|
|
6.
|
Ueno H, Kosuge T, Matsuyama Y, et al: A
randomised phase III trial comparing gemcitabine with surgery-only
in patients with resected pancreatic cancer: Japanese Study Group
of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer.
101:908–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Kindler HL, Friberg G, Singh DA, et al:
Phase II trial of bevacizumab plus gemcitabine in patients with
advanced pancreatic cancer. J Clin Oncol. 23:8033–8040. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Moore MJ, Goldstein D, Hamm J, et al:
Erlotinib plus gemcitabine compared with gemcitabine alone in
patients with advanced pancreatic cancer: a phase III trial of the
National Cancer Institute of Canada Clinical Trials Group. J Clin
Oncol. 25:1960–1966. 2007. View Article : Google Scholar
|
|
9.
|
Salomon DS, Brandt R, Ciardiello F and
Normanno N: Epidermal growth factor-related peptides and their
receptors in human malignancies. Crit Rev Oncol Hematol.
19:183–232. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Ueda S, Ogata S, Tsuda H, et al: The
correlation between cytoplasmic overexpression of epidermal growth
factor receptor and tumor aggressiveness: poor prognosis in
patients with pancreatic ductal adenocarcinoma. Pancreas. 29:e1–e8.
2004. View Article : Google Scholar
|
|
11.
|
Mendelsohn J and Baselga J: Status of
epidermal growth factor receptor antagonists in the biology and
treatment of cancer. J Clin Oncol. 21:2787–2799. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Cappuzzo F, Hirsch FR, Rossi E, et al:
Epidermal growth factor receptor gene and protein and gefitinib
sensitivity in non-small cell lung cancer. J Natl Cancer Inst.
97:643–655. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Hirsch FR, Varella-Garcia M, McCoy J, et
al: Increased epidermal growth factor receptor gene copy number
detected by fluorescence in situ hybridization associates with
increased sensitivity to gefitinib in patients with
bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group
Study. J Clin Oncol. 23:6838–6845. 2005. View Article : Google Scholar
|
|
14.
|
Tsao MS, Sakurada A, Cutz JC, et al:
Erlotinib in lung cancer – molecular and clinical predictors of
outcome. N Engl J Med. 353:133–144. 2005.
|
|
15.
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Han SW, Kim TY, Hwang PG, et al:
Predictive and prognostic impact of epidermal growth factor
receptor mutation in non-small cell lung cancer patients treated
with gefitinib. J Clin Oncol. 23:2493–2501. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Mitsudomi T, Kosaka T, Endoh H, et al:
Mutations of the epidermal growth factor receptor gene predict
prolonged survival after gefitinib treatment in patients with
non-small cell lung cancer with postoperative recurrence. J Clin
Oncol. 23:2513–2520. 2005. View Article : Google Scholar
|
|
18.
|
Paez JG, Janne PA, Lee JC, et al: EGFR
mutations in lung cancer: correlation with clinical response to
gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Takano T, Ohe Y, Sakamoto H, et al:
Epidermal growth factor receptor gene mutations and increased copy
numbers predict gefitinib sensitivity in patients with recurrent
non-small cell lung cancer. J Clin Oncol. 23:6829–6837. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Takano T, Ohe Y, Tsuta K, et al: Epidermal
growth factor receptor mutation detection using high-resolution
melting analysis predicts outcomes in patients with advanced
non-small cell lung cancer treated with gefitinib. Clin Cancer Res.
13:5385–5390. 2007. View Article : Google Scholar
|
|
21.
|
Sobin LH and Wittekind Ch: International
Union Against Cancer (UICC) TNM Classification of Malignant Tumors.
6th edition. Wiley-Liss; New York: 2002
|
|
22.
|
Tsuda H, Akiyama F, Terasaki H, et al:
Detection of HER-2/neu (c-erb B-2) DNA amplification in primary
breast carcinoma. Interobserver reproducibility and correlation
with immunohistochemical HER-2 overexpression. Cancer.
92:2965–2974. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Dembinski JL and Krauss S:
Characterization and functional analysis of a slow cycling stem
cell-like subpopulation in pancreas adenocarcinoma. Clin Exp
Metastasis. 26:611–623. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Willmarth NE, Baillo A, Dziubinski ML,
Wilson K, Riese DJ II and Ethier SP: Altered EGFR localization and
degradation in human breast cancer cells with an amphiregulin/EGFR
autocrine loop. Cell Signal. 21:212–219. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Barr S, Thomson S, Buck E, et al:
Bypassing cellular EGF receptor dependence through
epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis.
25:685–693. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Ueda S, Hatsuse K, Tsuda H, et al:
Potential crosstalk between insulin-like growth factor receptor
type 1 and epidermal growth factor receptor in progression and
metastasis of pancreatic cancer. Mod Pathol. 19:788–796.
2006.PubMed/NCBI
|
|
27.
|
Holbro T, Civenni G and Hynes NE: The ErbB
receptors and their role in cancer progression. Exp Cell Res.
284:99–110. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Madshus IH and Stang E: Internalization
and intracellular sorting of the EGF receptor: a model for
understanding the mechanisms of receptor trafficking. J Cell Sci.
122:3433–3439. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Sorkin A and Goh LK: Endocytosis and
intracellular trafficking of ErbBs. Exp Cell Res. 315:683–696.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Sorkin A and von Zastrow M: Endocytosis
and signalling: intertwining molecular networks. Nat Rev Mol Cell
Biol. 10:609–622. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Dittmann K, Mayer C, Kehlbach R and
Rodemann HP: Radiation-induced caveolin-1 associated EGFR
internalization is linked with nuclear EGFR transport and
activation of DNA-PK. Mol Cancer. 7:692008. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Li C, Iida M, Dunn EF, et al: Nuclear EGFR
contributes to acquired resistance to cetuximab. Oncogene.
28:3801–3813. 2009. View Article : Google Scholar : PubMed/NCBI
|
